SEC Tracker
Get the app
BICX · XBRL financial data

BioCorRx financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (BICX's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Revenue1019*4400*135178635(151)*21588
Cost of revenue413*2000*00——25145
Research and development287128*214536460273*1622971,005306*352712
Selling, general and administrative674694*7508301,193839*8861,2231,145539*775686
Total operating expenses972842*9721,3731,6601,125*1,0731,5922,581383*1,1711,554
Operating income (loss)(962)(823)*(969)(1,369)(1,660)(1,125)*(938)(1,414)(1,946)(534)*(956)(1,466)
Interest expense37104*182318149128*87373070*3130
Income tax expense (benefit)00*0000*00—year only00
Net income (loss)(867)(969)*(1,237)(1,234)(1,513)(1,271)*(841)(1,233)(1,918)553*(831)(965)
Earnings per share, diluted USD per share———(0.13)(0.14)—(0.06)(0.07)(0.11)—(0.03)(0.03)
Weighted average shares, basic thousands of shares———9,460———17,012————
Weighted average shares, diluted thousands of shares——2,941—10,908—3,55217,01218,163—25,60029,220

Balance sheet

CSV

Fiscal quarters (BICX's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents1566510180882411228813921221
Accounts receivable12100001125119425333068
Inventory—————013413415514314344
Total current assets2461871521723531185665271,4628141,020623
Property and equipment, net57514538321915118410
Right-of-use asset1779771218209199189180169159149138
Goodwill—————02,8402,8402,840563563563
Total assets5343893174796443866,8016,6817,5332,1472,3251,907
Accounts payable2,3902,4732,7732,8303,0963,0242,9683,7056,7264,0294,3554,440
Accrued liabilities—————————496—530
Total current liabilities5,9476,4317,1687,3158,2248,20813,44414,55915,0388,3068,5278,855
Lease liability, non-current7011018016915914913812811610493
Total liabilities9,79510,34111,18611,62612,64712,74118,60319,69420,29813,67413,94814,379
Accumulated deficit(77,134)(78,103)(79,340)(80,557)(82,045)(83,209)(84,051)(85,284)(87,202)(86,649)(87,481)(88,560)
Total stockholders' equity(9,132)(9,824)(10,739)(11,001)(11,831)(12,120)(11,556)(12,624)(13,485)(11,224)(11,450)(12,225)
Total liabilities and equity5343893174796443866,8016,6817,5332,1472,3251,907
Common shares outstanding (cover page) thousands of shares8,5998,8159,61310,89112,74916,09916,99718,91223,68526,40329,05629,758

Cash flows

CSV

Fiscal quarters (BICX's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(867)(969)*(1,237)(1,234)(1,513)(1,271)*(841)(1,233)(1,918)553*(831)(965)
Stock-based compensation1638*1983029286*151156*(66)*351*108122*
Depreciation and amortization—————year only25——year only11—
Net cash from operating activities(351)*(534)*(340)(152)*(358)*(247)*(690)(126)*(634)*(848)*(433)(440)*
Proceeds from issuing common stock0*—0——700*7000*(684)*———
Net cash from financing activities310*443*37659*349*335*626214*810*699*506250*

Compare with peers

SIC 8093 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 8093 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
BioCorRx2188(440)*29.8M0.0 quarters 10-QJun 30, 2026
Pacific Health Care Organization2,2401,775(5.2)*12.8M427.9 quarters 10-QJun 30, 2026
AnTix Holdings14not reportednot reported70.7M— 10-KJun 30, 2025
Marpai1384,166(4,099)*26.8M0.0 quarters 10-QJun 30, 2026
BioRestorative Therapies3,11323(3,808)25.5M0.9 quarters 10-QMar 31, 2026
IMAC Holdings4521(1,434)*3.8M0.0 quarters 10-QSep 30, 2025

Not investment advice. Not affiliated with the U.S. SEC.